FindTrial
Sign In

Comparision of the tolerability, response rates and cost analysis among the breast cancer patients receiving neoadjuvant chemotherapy - a randomized control trial

Comparision of the tolerability, response rates and cost analysis among the patients receiving weekly paclitaxel versus three weekly docetaxel as a part of neo adjuvant chemotherapy for breast cancer patients-a randomized control trial - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2024/11/076131
Enrollment
60
Registered
2024-11-01
Start date
Unknown
Completion date
Unknown
Last updated
2025-07-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: C508- Malignant neoplasm of overlappingsites of breast

Interventions

Intervention1: paclitaxel: weekly paclitaxel is given for 12 weeks prior to surgery Control Intervention1: Docetaxel: three weekly docetaxel is given to patient for 12 weeks prior to surgery

Sponsors

Postgraduate institute of medical education and research
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1 locally advanced breast cancer

Exclusion criteria

Exclusion criteria: 1 patient denying consent

Design outcomes

Primary

MeasureTime frame
1.To compare the tolerability among the patients receiving weekly paclitaxel versus three weekly docetaxel as a part of neo adjuvant chemotherapy for breast cancer patients.Timepoint: At 4 weeks,8 weeks,12 weeks of neo adjuvant chemotherapy followed by 4 weeks after surgery—

Secondary

MeasureTime frame
to access cost analysis and response rate including side effectsTimepoint: 1 month after surgery—

Countries

India

Contacts

Public ContactGOURAV KUMAR DEV

Postgraduate Institute of medical education and research

khare.siddhant@gmail.com7838796305

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026